Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
Discover Tomorrow's Bullish Stocks Today
Analyst Views on DERM
About DERM
About the author
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
